These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23101960)

  • 21. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of intermittent androgen deprivation therapy in the management of biochemically recurrent or metastatic prostate cancer.
    Jaswal J; Crook J
    Curr Urol Rep; 2015 Mar; 16(3):11. PubMed ID: 25677230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of side effects of androgen deprivation therapy.
    Grossmann M; Zajac JD
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):655-71, x. PubMed ID: 21889727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
    Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
    Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement.
    Trost LW; Serefoglu E; Gokce A; Linder BJ; Sartor AO; Hellstrom WJ
    J Sex Med; 2013 Feb; 10 Suppl 1():84-101. PubMed ID: 23387914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
    Leahy Y
    Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complications of androgen deprivation therapy: prevention and treatment.
    Holzbeierlein JM; Castle E; Thrasher JB
    Oncology (Williston Park); 2004 Mar; 18(3):303-9; discussion 310, 315, 319-21. PubMed ID: 15065701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Metabolic disorder after androgen deprivation therapy in patients with prostate cancer].
    Yuan JQ; Zhang XW; Xu T; Wang XF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Aug; 33(4):468-72. PubMed ID: 21906460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Metastatic prostate cancer].
    Droz JP; Flechon A; Terret C
    Rev Prat; 2003 Dec; 53(20):2258-62. PubMed ID: 15018080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Observational study CAPITAL and prescription of hormonotherapy by French urologists in daily practice].
    de La Taille A; Drouin SJ; Rouprêt M; Perrin P; Zerbib M
    Prog Urol; 2009 Apr; 19 Suppl 1():S20-5. PubMed ID: 19465333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen deprivation therapy for prostate cancer.
    Sharifi N; Gulley JL; Dahut WL
    JAMA; 2005 Jul; 294(2):238-44. PubMed ID: 16014598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Association of radiotherapy and hormonotherapy in locally advanced prostate cancer].
    Quero L; Wong-Hee-Kam S; Rivera S; Hennequin C
    Bull Cancer; 2012 Jul; 99 Suppl 1():S30-6. PubMed ID: 22516590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complications of androgen-deprivation therapy in prostate cancer: the other side of the coin.
    Hoffmann P; Schulman C
    BJU Int; 2009 Apr; 103(8):1020-3. PubMed ID: 19348058
    [No Abstract]   [Full Text] [Related]  

  • 34. Metabolic effects of androgen deprivation therapy.
    Choi SM; Kam SC
    Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison.
    Gonzalez BD; Jim HS; Donovan KA; Small BJ; Sutton SK; Park J; Lin HY; Spiess PE; Fishman MN; Jacobsen PB
    J Urol; 2015 Sep; 194(3):690-5. PubMed ID: 25791402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of androgen in the elderly. Problems of androgen deprivation therapy].
    Tsujimura A
    Clin Calcium; 2013 Aug; 23(8):1185-90. PubMed ID: 23892220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.
    Mottet N; Prayer-Galetti T; Hammerer P; Kattan MW; Tunn U
    BJU Int; 2006 Jul; 98(1):20-7. PubMed ID: 16566812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Andropause syndrome in men treated for metastatic prostate cancer: a qualitative study of the impact of symptoms.
    Grunfeld EA; Halliday A; Martin P; Drudge-Coates L
    Cancer Nurs; 2012; 35(1):63-9. PubMed ID: 21558849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathologic effects of testosterone deprivation.
    Sprenkle PC; Fisch H
    Curr Opin Urol; 2007 Nov; 17(6):424-30. PubMed ID: 17921778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.